Biomea Fusion Inc (NASDAQ:BMEA) presented new preclinical data at the American Association of Cancer Research (AACR) Annual Meeting for BMF-219 in liquid cancers and solid tumors.
- BMF-219 exhibited cytotoxic activity as a single agent at similar concentrations across multiple preclinical patient-derived (PDX) models ex vivo, including diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic cancer.
- In addition, the company presented a Trial In Progress (TIP) poster presentation detailing the design of Biomea's ongoing Phase 1 clinical trial (COVALENT-101).
- The company said that in comparison to two highly specific KRAS G12C inhibitors, BMF-219 exhibited broader potency across KRAS-mutated cell lines (G12C, G12D, G13D, and G12V) and ex vivo PDX tumor models, indicating pan-KRAS activity with over 90% growth inhibition in most of these models.
- Additionally, BMF-219 could increase the depth of response across G12C cell lines, notably achieving a higher percentage of cell killing in G12C colorectal cancer cells than commercially available Amgen Inc's (NASDAQ:AMGN) Lumakras (sotorasib) and another clinical-stage KRAS inhibitor.
- Price Action: BMEA shares traded 1.75% lower at $4.50 on the last check Monday.
